With the dust settling after the recent rights issue, Nanexa now progresses with its more focused roadmap, concentrating on Phase I trials with NEX-22 in Q1’24, preparation for Phase Ib trials with NEX-20, and the partner projects. With a cash position of SEK 84m, there is a financial runway through 2024, but also a higher pressure to reach a licensing agreement soon. Following a revision of the projects, we’ve increased our Likelihood of Approvals (LOA) for NEX-20 and NEX-22 to 20% and 15% respectively (up from 9.2% and 7.5%). This, coupled with a wide range of possible outcomes for the company’s projects, supports a high potential relative to the current share price. We now look forward to the Phase I trial with NEX-22 and more positive news flow from the partner projects as triggers in 2024, and expect that the worldwide GLP-1 story will start to gain traction also for the Nanexa share soon.
Johan Widmark | 2023-11-21 08:00
This commissioned research report is for informational purposes only and is to be considered marketing communication. This research report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and Emergers is not subject to any prohibition on dealing ahead of the dissemination of investment research. This research does not constitute investment advice and is not a solicitation to buy shares. For more information, please refer to disclaimer.
Progress in NEX-20 and NEX-22 during fall
Revenues in Q3’23 amounted to SEK 6.7m, of which most, SEK 5.6m, was accrual of deferred revenue from the Novo Nordisk deal. Cash flow came in at SEK -18m in Q3’23, and SEK -61m year to date. In terms of development, Q3’23 saw the pharmacokinetic data from the Phase 1 study with NEX-20, which was then followed by final safety and tolerability data in October. Nanexa also completed a preclinical study of NEX-22 in minipigs confirming the long release profile of liraglutide, previously seen in rats. The company also reports of positive developments in the collaboration with Novo Nordisk and other partner projects.Streamlining with focus on NEX-22 and partner projects
The key event during fall was the rights issue that netted the company SEK 63m after costs, putting cash at SEK 84m. As we’ve highlighted earlier, the lower than intended capital raised (SEK 75m compared to the targeted SEK 121m), actually represents a sobering streamlining, as the focus forward will now be on the most promising and lucrative assets in the portfolio – the long-acting depot formulation of GLP-1 agonist liraglutide and the partner project with largest shareholder Novo Nordisk – which are also the ones that holds the most attraction for investors.Revision of LOA
Following a revision of the projects, where we especially take note of the recent successful completion of Phase I with NEX-20, the recommitment from Novo Nordisk in the recent rights issue, continued positive development in partner development with Novo Nordisk and the preclinical study in minipigs showing a long release profile of liraglutide, we’ve now raised our risk-adjustment for NEX-20 and NEX-22 to 20% and 15%, respectively (from 9.2% and 7.5%). After a revision also of our fundamental estimates, this motivates a hike in our total rNPV to SEK 4.3-11.6 (3.2-10.5) per share, as we continue to see a wide range of potential outcomes for the company’s various projects and partnerships.
DISCLAIMER
This commissioned research report is for informational purposes only and is to be considered marketing communication. This research does not constitute investment advice and is not a solicitation to buy shares. Information provided here or on Emergers’ website emergers.se is not intended to be financial advice. This research shall not be construed as a recommendation or solicitation to invest in the companies described. Emergers cannot be held liable for either direct or indirect damages caused by decisions made on the basis of information in this analysis. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.
This material is not intended to be financial advice. This material has been commissioned by the Company in question and prepared and issued by Emergers, in consideration of a fee payable by the Company. Emergers charges a standard fee for the production and broad dissemination of a detailed note following by regular update notes. Fees are paid upfront in cash without recourse. Emergers may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.
Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained herein represent those of the research analyst at Emergers at the time of publication. The company has been given the opportunity to influence factual statements before publication, but forecasts, conclusions and valuation reasoning are Emergers’ own. Forward-looking information or statements contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.
Exclusion of Liability: To the fullest extent allowed by law, Emergers shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained in this material.
No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Emergers’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in this material may not be eligible for sale in all jurisdictions or to certain categories of investors. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.
Investment in securities mentioned: Emergers has a restrictive policy relating to personal dealing and conflicts of interest. Emergers does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Emergers may have a position in any or related securities mentioned in this report, subject to Emergers’ policies on personal dealing and conflicts of interest.
Copyright: Copyright 2023 Incirrata AB (Emergers)
United Kingdom
This document is prepared and provided by Emergers for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the ”FPO”) (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.
This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.
United States
Emergers relies upon the ”publishers’ exclusion” from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Emergers does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
